Басты бетке
4.6/5
TrustPilot

Рамәт-Ғанда ең жақсы Иммунотерапия Кейтрудой (Пембролизумаб) дәрігерлері - ЖОҒ-5 дәрігерлер

Израиль еліндегі үздік Иммунотерапия Кейтрудой (Пембролизумаб) дәрігерлердің бағаларын салыстырыңыз. Өз үздік сәйкестіңізді осы жерден табыңыз.

Израиль еліндегі Иммунотерапия Кейтрудой (Пембролизумаб) бойынша үздік 3 маманнан баға ұсыныстарын алыңыз

Біз сіздің қажеттіліктеріңіз бен бюджетіңізге қарай ең жақсы дәрігерлерді қолмен таңдаймыз.

Үздік дәрігерлер

5

Израиль

Пікірлер

14000+

Нағыз науқастардан

Дәрігер қызметтеріне ең жақсы баға ұсынатын елді таңдаңыз

Үздік елдердегі Иммунотерапия Кейтрудой (Пембролизумаб) бағаларын салыстырыңыз

Үздік дәрігерлер мен бағаны көру үшін елді түртіңіз

Turkey
Ukraine
South Korea
Mexico
Czech Republic
Canada
$3,300 - $10,000
$4,500 - $8,000
$5,200 - $8,500
$7,000 - $11,000
$7,500 - $10,500
$7,800 - $11,200
$0
$2,000
$4,000
$6,000
$8,000
$10,000
$12,000

Тегін жеке емдеу жоспарын алыңыз және ең жақсы нұсқаны таңдаңыз. Міндеттеме жоқ · Біздің қызметтер үшін төлем болмайды

Hana Golan

  • 24 жылдар тәжірибе
  • Орналасқан жері: Израиль, Рамәт-Ған
  • Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.

    She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.

    She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.

    She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша

Yuri Goldes

  • 28 жылдар тәжірибе
  • Орналасқан жері: Израиль, Рамәт-Ған
  • Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

    He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

    He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша

Raanan Berger

  • 27 жылдар тәжірибе
  • Орналасқан жері: Израиль, Рамәт-Ған
  • Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

    He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша

Jair Bar

  • 35 жылдар тәжірибе
  • Орналасқан жері: Израиль, Рамәт-Ған
  • Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

    He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

    He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша

Eytan Aharon Ben-ami

  • 20 жылдар тәжірибе
  • Орналасқан жері: Израиль, Рамәт-Ған
  • Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

    He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

    He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша

Шетелде клиника таңдау қиын болуы мүмкін. Bookimed командасы 800 мыңнан астам науқасқа көмектесті және Сіздің алаңдаушылықтарыңызды түсінеді. Біз сенімді дәрігерлерді, баға мен сапаның ең жақсы арақатынасы бар нұсқаларды және тіпті күрделі жағдайлар үшін шешімдерді қалай табуды білеміз. Біз осы жолдың әрбір қадамында Сізді қолдауға дайынбыз.

Ян Мациевский

Дәрігер-координаторлар тобының басшысы

4300++ науқас сапары бойынша сүйемелдеу жасалды

3 жылдар тәжірибе Bookimed-те

Осы айда Israel елінен 142 науқас өз дәрігерін біздің көмегімізбен тапты

Үздік дәрігерге сәйкестік қалай жүргізіледі

1

2 минуттық сауалнама

Бізге мақсатыңызды, бюджетіңізді, уақыт мерзімін айтыңыз

2

Адамдық сәйкестік + AI

Біздің алгоритм сәйкестік табады, үйлестіруші сәйкес келетінін тексереді

3

Сіздің опцияларыңыз дайын

Бағаларды, пакеттерді, күндерді салыстырыңыз. Үйлестірушіңізбен сөйлесіңіз

Таңдаудан шатастыңыз ба?

Жеке Bookimed үйлестірушісі сіздің қажеттіліктеріңізге сәйкес идеалды хирургты табуға көмектеседі

  • Сізді әр кезеңде <b>24</b>/<b>7</b> қолдайды
  • Сізге дәрігерді сәйкестендіруге көмектеседі және клиникалармен барлық байланысқа жауапты
  • Сіздің сапарыңызды, тұрғылықты жеріңізді және тасымалдануыңызды үйлестіреді

Сіздің емдеуді бағыттау

Медицина мамандығы бар жеке үйлестірушілер

Peguy Beaugris
Tetyana Hyrych
Zekra Eldeeb
Victoria Olayinka
Iryna Sydorchuk
Tetiana Ihnatiuk

Дәрігер мен клиниканы дұрыс қалай таңдау керек: сарапшылардың ұсыныстары

Дәрігер немесе клиника таңдағанда осы негізгі сәттерді есте сақтаңыз:
Біліктілікті тексеріңіз
ISAPS, JCI және т.б. сияқты ұйымдардан сертификаттардың болуына көз жеткізіңіз.
Процедуралардың табыстылығы туралы біліңіз
Сізге қажет саладағы үлкен тәжірибесі бар дәрігерлерді таңдаңыз.
Науқастардың пікірлерін оқыңыз
Олардың тәжірибесі туралы тікелей білу үшін Bookimed сайтындағы нақты науқастардың пікірлерімен танысыңыз.
Тиімді коммуникация мүмкіндігіне көз жеткізіңіз
Сіздің барушы максималды жайлы өтуі үшін аудармашы қызметтерін ұсынатын клиникаларды таңдаңыз.
Қолжетімді қызметтер туралы сұраңыз
Жасырын шығындарды болдырмас үшін бағаға тұру, жергілікті трансфер және кейінгі күтім сияқты қызметтер кіретінін растаңыз.

Bookimed сараптамасы: Израильдің еліндегі жетекші иммунотерапияның кейтрудой (пембролизумаб) мамандары (2026)

Bookimed Израильдің елінде Иммунотерапия Кейтрудой (Пембролизумаб) бойынша 15 сұранысты үйлестірді, 5 маманмен жұмыс істейді. Осы кестедегі дәрігерлер өз біліктілігімен және науқастардың ерекше қажеттіліктерін шешудегі тәжірибесімен ерекшеленіп тұрады. 2026 рейтингінде барлық ақпарат нақты науқастардың жағдайлары мен серіктес клиникалардың ағымдағы бағдарламаларынан алынған растаулы деректерге негізделген.
РейтингДәрігертәжірибеСәйкес келеді үшінОларды өзгелерден ерекшелендіретін ерекшеліктеріКлиника және орныКонсультация

FAQ

Бұл Bookimed арқылы медициналық көмек іздейтін нақты науқастардың сұрақтары. Оларға тәжірибелі дәрігер-координаторлар мен клиникалардың ресми өкілдері жауап береді.

Israel's leading oncologists for Keytruda therapy include Professor Ofer Merimsky and Dr. Irina Stepfansky at Sourasky Medical Center. These specialists possess extensive experience in managing immunotherapy for lung cancer, melanoma, and sarcomas. They hold prestigious European Society of Medical Oncology (ESMO) certifications and lead international clinical trials.

  • Professor Ofer Merimsky: Leads the bone and soft tissue oncology unit at Sourasky Medical Center.
  • Dr. Irina Stepfansky: Directs oncology hospitalization and oversees advanced Phase I-III clinical immunotherapy trials.
  • Dr. Ari Raphael: Specializes in thoracic malignancies and genomic profiling for personalized Keytruda treatment protocols.
  • Professor Nir Peled: Recognized as a leading specialist for lung cancer immunotherapy at Herzliya Medical Center.

Bookimed Expert Insight: Data shows a strong trend of international training among Israel's top immunotherapy providers. Dr. Ari Raphael and Dr. Pelles Sharon completed specialized training at renowned UK centers like Guy's and St. Thomas and Royal Marsden. This global exposure allows them to implement the latest international protocols for monitoring immune-related side effects effectively.

Patient Consensus: Patients often note that major centers like Sourasky and Hadassah offer efficient access to Keytruda. While they focus on insurance and coverage, many express relief at the thorough monitoring for immune reactions. Those starting treatment appreciate the clear communication from nursing teams during the initial infusion cycles.

Verify an Israeli oncologist is certified to administer Keytruda by confirming their board certification in medical oncology. Qualified specialists hold licenses from the Israel Ministry of Health. They typically practice at JCI-accredited institutions like Sourasky Medical Center or Hadassah Medical Center.

  • Ministry of Health: Doctors must hold an active Israeli medical license and oncology specialization.
  • Hospital affiliation: Keytruda is dispensed only through approved oncology departments at major medical centers.
  • International memberships: Top specialists often belong to the American Society of Clinical Oncology (ASCO).
  • Academic credentials: Search for researchers like Dr. David Sarid who lead clinical immunotherapy trials.

Bookimed Expert Insight: Data shows that leading Israeli immunotherapy experts maintain dual affiliations with global research bodies. For example, Dr. Ofer Merimsky at Sourasky Medical Center is an ESMO faculty member. These connections enable doctors to apply the latest global pembrolizumab protocols before they become standard practice elsewhere.

Patient Consensus: Patients note that verifying a doctor's current hospital affiliation is a reliable way to ensure they can access genuine Keytruda. Many patients felt more secure after seeing the official Ministry of Health license scan. They also realized that while no specific Keytruda-only certificate exists, oncology board certification is the gold standard.

Which Israeli hospitals have the most active immunotherapy programs with Keytruda?

Sourasky Medical Center and Hadassah Medical Center lead Israel's immunotherapy landscape with extensive Keytruda programs. These institutions feature dedicated oncology divisions and specialized research units. They provide access to advanced protocols for melanoma, lung cancer, and gastrointestinal malignancies through international clinical trials and expert coordination.

  • Specialized oncology divisions: Sourasky (Ichilov) houses the first laboratory accredited for PD-L1 expression testing.
  • Gastrointestinal expertise: Dr. Auala Hubert at Hadassah leads immunotherapy for complex digestive system cancers.
  • Pediatric programs: Dana Dwek Children's Hospital at Sourasky offers specialized immunotherapy for pediatric oncology.
  • Advanced sarcoma treatment: Professor Ofer Merimsky pioneers Keytruda protocols for complex bone and soft tissue tumors.

Bookimed Expert Insight: Data shows that Sourasky Medical Center is a premier hub for complex cases due to its multi-disciplinary leadership. Dr. Ido Wolf chairs the National Council for Oncology, while Dr. David Sarid, trained at Oxford, leads clinical trials. This concentration of national leadership and international training allows patients to access treatment plans that align with the latest global standards.

Patient Consensus: Patients note that arriving with your own pathology slides can help avoid diagnostic delays in the busy Tel Aviv centers. Many describe a feeling of deep relief when accessing compassionate-use programs for advanced cancers in Jerusalem. Those who traveled to Israel emphasize that having a coordinator is vital to navigate the hospital bureaucracy quickly.

What criteria do Israeli doctors use to decide if a patient is eligible for Keytruda?

Israeli oncologists determine Keytruda eligibility by evaluating tumor biomarkers, specific cancer types, and previous treatment results. They prioritize genetic profiling and PD-L1 expression levels to confirm the therapy will be effective. Doctors also check if the patient meets the strict criteria outlined in the national health basket.

  • Biomarker testing: Doctors require evidence of PD-L1 expression, often at thresholds of 1% or 50%.
  • Genetic profiling: Eligibility often depends on Microsatellite Instability-High (MSI-H) or high Tumor Mutational Burden (TMB-H).
  • Cancer indications: Treatment is typically approved for advanced melanoma, non-small cell lung cancer, and HNSCC.
  • Treatment history: For some cancers, patients must first show resistance to standard chemotherapy or surgery.

Bookimed Expert Insight: Israeli specialists often combine clinical practice with genomic research to refine eligibility. For instance, Dr. Ari Raphael at Sourasky Medical Center serves as a principal investigator for Keytruda clinical trials. This dual role allows doctors to use NGS interpretation and T-cell studies to identify eligibility for patients who might not meet standard criteria. Consultations with experts like Dr. Irina Stepfansky, starting from $750, often include reviews of Phase I-III trial opportunities.

Patient Consensus: Patients note that having clear genetic test results like FoundationOne is essential to avoid treatment denials. They often describe a waiting period for committee approval but find that high PD-L1 levels speed up the process. Many are relieved that doctors also consider compassionate use for complex cases when standard benchmarks are not met.

Do the same doctors who prescribe Keytruda in Israel also handle side-effect management, or is care transferred?

Oncologists in Israel who prescribe Keytruda typically manage your entire treatment journey including side-effect monitoring. They remain your primary contact for evaluating blood work and symptoms before infusions. While they may consult sub-specialists for specific organ issues, the oncology team coordinates all corrective care.
  • Primary oversight: Prescribing oncologists like Dr. Pelles Sharon lead all initial side-effect assessments.
  • Specialist collaboration: Oncology teams consult internal endocrinologists or pulmonologists for immune-related reactions.
  • Patient alert cards: Israel uses standardized cards to help other doctors report reactions back to oncologists.
  • Continuous monitoring: Doctors at JCI-accredited centers like Sourasky manage fatigue, rashes, and digestive issues.

Bookimed Expert Insight: Data shows that top Israeli oncologists often hold dual research and clinical trial roles. For instance, Dr. David Sarid at Sourasky Medical Center is a principal investigator for clinical trials. This means these doctors often have earlier access to updated protocols for managing complex immunotherapy reactions before they become standard global practice.

Patient Consensus: Patients note their oncologists act as a central figure for infusions and monitoring without transferring care elsewhere. They appreciate that thyroid issues or rashes are handled within the same hospital system. Many feel this approach is much more organized than having to visit separate clinics for every side effect.

A first consultation with an Israeli Keytruda specialist typically costs between $750 and $950 for medical tourists. These fees cover a comprehensive review by senior oncologists at JCI-accredited facilities like Sourasky Medical Center. Leading experts often have international training from institutions like Oxford or the Royal Marsden.

  • Consultation price range: Specialists charge from $750 to $950 for initial evaluations.
  • Expert credentials: Doctors often hold memberships in ESMO and ASCO for global standards.
  • Specialized sub-types: Experts focus on Keytruda for sarcomas, lung cancer, and GI tumors.
  • Leading facilities: Consultations occur at hospitals ranked among Newsweek's World's Best Smart Hospitals.

Bookimed Expert Insight: Data shows that choosing a director-level specialist doesn't always mean a higher price. Dr. Irina Stepfansky and Dr. Ari Raphael, both leading oncology programs at Sourasky Medical Center, offer consultations starting from $750. This is lower than some other senior specialists in the same facility. Patients can access top-tier clinical trial investigators for the same fee as a standard oncology review.

Patient Consensus: Patients note that arriving with organized records helps make the most of the initial meeting. Many felt relieved by how clearly doctors explained the immunotherapy process. They often mentioned that while fees are paid upfront, the level of detail provided is very high.

How can I compare Keytruda doctors in Israel if I only have virtual consultations available?

You can compare Keytruda doctors in Israel remotely by evaluating their clinical trial leadership, specialized fellowships, and hospital affiliations. Leading oncologists at JCI-accredited centers like Sourasky Medical Center offer video consultations to review genomic profiling and design personalized immunotherapy protocols before you travel.

  • Clinical trial leadership: Dr. Ari Raphael at Sourasky serves as a principal investigator for Keytruda trials.
  • International fellowship training: Prof. Ofer Merimsky completed advanced oncology training at Institut Gustave Roussy in Paris.
  • Sub-specialization focus: Dr. Pelles Sharon focuses on gastrointestinal tumors while Dr. Sonnenblick specializes in breast cancer.
  • Consultation accessibility: Top specialists provide virtual second opinions with fees ranging from $750 to $950.

Bookimed Expert Insight: Data shows a clear distinction between general oncologists and those leading Phase I-III immunotherapy trials. For complex cases, patients should prioritize doctors like Dr. Irina Stepfansky at Sourasky, who directs oncology hospitalization and manages high-level clinical research. These specialists often have earlier access to emerging combination protocols that general practitioners may not yet utilize.

Patient Consensus: Patients note it is helpful to ask doctors specific questions about how many Keytruda cycles they have managed for a particular cancer type. They suggest recording virtual sessions to compare the confidence and phrasing of different specialists side-by-side. Many felt more secure choosing doctors tied to major institutional centers like Hadassah or Sourasky due to their strict training standards.